Do you want to read an article? Please log in or register.
The Association of Severe Hypoglycemia With Incident Cardiovascular Events and Mortality in Adults With Type 2 Diabetes
Diabetes - GeneralGlycemic Control
COMMENTED
Related content
COMMENTED
Diabetes - GeneralType 2 Diabetes
Effect of population screening for type 2 diabetes and cardiovascular risk factors on mortality rate and cardiovascular events: a controlled trial among 1,912,392 Danish adults
Diabetologia.
Simmons RK, Griffin SJ, Witte DR, Borch-Johnsen K, Lauritzen T, Sandbæk A
doi: 10.1007/s00125-017-4323-2.
COMMENTED
Type 2 Diabetes
Risk of Major Adverse Cardiovascular Events, Severe Hypoglycemia, and All-Cause Mortality for Widely Used Antihyperglycemic Dual and Triple Therapies for Type 2 Diabetes Management: A Cohort Study of All Danish Users
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
doi: 10.2337/dc19-2535.
Diabetes - GeneralType 2 Diabetes
The Impact of Liraglutide on Diabetes-Related Foot Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events: Results From the LEADER Trial
Diabetes Care.
Dhatariya K, Bain SC, Buse JB, Simpson R, Tarnow L, Kaltoft MS, Stellfeld M, Tornøe K, Pratley RE; LEADER Publication Committee on behalf of the LEADER Trial Investigators
doi: 10.2337/dc18-1094.
Diabetes - GeneralType 2 Diabetes
Empagliflozin reduces cardiovascular events, mortality and renal events in participants with type 2 diabetes after coronary artery bypass graft surgery: subanalysis of the EMPA-REG OUTCOME® randomised trial
Diabetologia.
Verma S, Mazer CD, Fitchett D, Inzucchi SE, Pfarr E, George JT, Zinman B
doi: 10.1007/s00125-018-4644-9.
Diabetes - GeneralType 2 Diabetes
Higher Plasma Methylglyoxal Levels Are Associated With Incident Cardiovascular Disease and Mortality in Individuals With Type 2 Diabetes
Diabetes Care.
Hanssen NMJ, Westerink J, Scheijen JLJM, van der Graaf Y, Stehouwer CDA, Schalkwijk CG5; SMART Study Group
doi: 10.2337/dc18-0159.
Diabetes - GeneralType 2 DiabetesGlycemic Control
Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial
Lancet Diabetes Endocrinol.
Vaccaro O, Masulli M, Nicolucci A, Bonora E, Del Prato S, Maggioni AP, Rivellese AA, Squatrito S, Giorda CB, Sesti G, Mocarelli P, Lucisano G, Sacco M, Signorini S, Cappellini F, Perriello G, Babini AC, Lapolla A, Gregori G, Giordano C, Corsi L, Buzzetti R, Clemente G, Di Cianni G, Iannarelli R, Cordera R, La Macchia O, Zamboni C, Scaranna C, Boemi M, Iovine C, Lauro D, Leotta S, Dall'Aglio E, Cannarsa E, Tonutti L, Pugliese G, Bossi AC, Anichini R, Dotta F, Di Benedetto A, Citro G, Antenucci D, Ricci L, Giorgino F, Santini C, Gnasso A, De Cosmo S, Zavaroni D, Vedovato M, Consoli A, Calabrese M, di Bartolo P, Fornengo P, Riccardi G; Thiazolidinediones Or Sulfonylureas Cardiovascular Accidents Intervention Trial (TOSCA.IT) study group; under the mandate of the Italian Diabetes Society
doi: 10.1016/
COMMENTED
Type 2 Diabetes
Association of Second-line Antidiabetic Medications With Cardiovascular Events Among Insured Adults With Type 2 Diabetes
JAMA Netw Open.
O’Brien MJ, Karam SL, Wallia A, Kang RH, Cooper AJ, Lancki N, Moran MR, Liss DT, Prospect TA, Ackermann RT
doi: 10.1001/jamanetworkopen.
COMMENTED
Type 2 Diabetes
Association of moderate and vigorous physical activity with incidence of type 2 diabetes and subsequent mortality: 27 year follow-up of the Whitehall II study
★ 1
Recommended and commented by
Prof. emer. Dr Ulrich Keller, Faculty Member
Diabetologia.
Yerramalla MS, Fayosse A, Dugravot A, Tabak AG, Kivimäki M, Singh-Manoux A, Sabia S
doi: 10.1007/s00125-019-05050-1.
Diabetes - GeneralType 2 Diabetes
Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis
Lancet Diabetes Endocrinol.
Birkeland KI, Jørgensen ME, Carstensen B, Persson F, Gulseth HL, Thuresson M, Fenici P, Nathanson D, Nyström T, Eriksson JW, Bodegård J, Norhammar A
doi: 10.1016/